کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3361592 1592044 2016 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C
چکیده انگلیسی


• Resistance-associated variants (RAVs) however may also naturally occur and may be found prior to treatment.
• The clinical impact of this basal resistance still remains uncertain.
• Drug resistance analyses can be beneficial and necessary in revealing which variants are responsible for the pre-treatment natural resistance, indicating which mutations are responsible for the viral breakthrough that may develop during the treatment, and for the selection of additional treatments.

BackgroundDrug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals.Materials and methods178 antiviral-naïve patients infected with HCV genotype 1 were selected from 27 clinical centers of various geographical regions in Turkey and included in the current study. The basal NS3 Pls resistance mutations of these patients were analyzed.ResultsIn 33 (18.5%) of the patients included in the study, at least one mutation pattern that can cause drug resistance was identified. The most frequently detected mutation pattern was T54S while R109K was the second most frequently detected. Following a more general examination of the patients studied, telaprevir (TVR) resistance in 27 patients (15.2%), boceprevir (BOC) resistance in 26 (14.6%) patients, simeprevir (SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in 13 (7.3%) patients were detected. Our investigation also revealed that rebound developed in the presence of a Q80K mutation and amongst two V55A mutations following treatment with TVR, while no response to treatment was detected in a patient with a R55K mutation.ConclusionWe are of the opinion that drug resistance analyses can be beneficial and necessary in revealing which variants are responsible for pre-treatment natural resistance and which mutations are responsible for the viral breakthrough that may develop during the treatment.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Infectious Diseases - Volume 50, September 2016, Pages 1–5
نویسندگان
, , , , , , , , , , , , , , , , ,